Trial Profile
Phase I trial of cabozantinib + enzalutamide for the treatment of castration-resistant prostate cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 05 Dec 2013
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Enzalutamide
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Exelixis
- 05 Dec 2013 New trial record